Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

39 results about "Radiosynthesis" patented technology

Radiosynthesis is a Fully automated synthesis method in which radioactive compounds are produced. Radiosynthesis is generally carried out by several nuclear interface modules, which are protected by the lead shielding and controlled by a computer semi-automatically. The set-ups of modules are different depending on the type of product and synthesis process. Consequently, the modules should be adapted with the synthesis stages. In some cases, such stages of synthesis are carried out manually in order to optimize the radiochemical yield or due to the incompatibility or lack of module.

Modular System for Radiosynthesis with Multi-Run Capabilities and Reduced Risk of Radiation Exposure

InactiveUS20110150714A1Fast and efficient and compact and safe to operatorMinimize exposureIon-exchange process apparatusIon-exchanger regenerationRadiosynthesisRadiation exposure
Macro- and microfluidic devices and related technologies, and chemical processes using such devices. More specifically, the devices may be used for a fully automated synthesis of radioactive compounds for imaging, such as by positron emission tomography (PET), in an efficient, compact and safe to the operator manner. In particular, embodiments of the present invention relate to an automated, multi-run, microfluidic instrument for the multi-step synthesis of radiopharmaceuticals, such as PET probes, comprising a remote shielded mini-cell containing radiation-handing components.
Owner:SIEMENS MEDICAL SOLUTIONS USA INC

Microfluidic radiosynthesis system for positron emission tomography biomarkers

InactiveUS20090036668A1Fast and efficient and compact mannerSmall amountGaseous chemical processesSugar derivativesHands freeEngineering
Methods and devices for a fully automated synthesis of radioactive compounds for imaging, such as by positron emission tomography (PET), in a fast, efficient and compact manner are disclosed. In particular, the various embodiments of the present invention provide an automated, stand-alone, hands-free operation of the entire radiosynthesis cycle on a microfluidic device with unrestricted gas flow through the reactor, starting with target water and yielding purified PET radiotracer within a period of time shorter than conventional chemistry systems. Accordingly, one aspect of the present invention is related to a microfluidic chip for radiosynthesis of a radiolabeled compound, comprising a reaction chamber, one or more flow channels connected to the reaction chamber, one or more vents connected to said reaction chamber, and one or more integrated valves to effect flow control in and out of said reaction chamber.
Owner:SIEMENS MEDICAL SOLUTIONS USA INC

Microfluidic radiosynthesis of a radiolabeled compound using electrochemical trapping and release

InactiveUS20090095635A1Faster and robust operationHigh radiochemical labeling yieldCellsElectrolytic organic productionMicroreactorChemical synthesis
Methods and apparatus enable radiosynthesis of radiolabeled compounds using electrochemical trapping and release. The trapping and release of radioactive isotopes all occur inside a microreactor, a vial or similar device, thus eliminating the need for azeotropic drying and several dead-end filling steps, as well as the necessity to move concentrated radioisotopes from one compartment of the chip to another. These and other features allow radioisotope enrichment to be carried out internally within a radiochemical synthesis chip, providing faster and more robust operation, as well as producing very high radiochemical labeling yields.
Owner:CAL TECH +1

Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase

Novel epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors, pharmaceutical compositions including same and their use in the treatment of EGFR-TK related diseases or disorders are disclosed. Novel radiolabeled EGFR-TK inhibitors as their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are further disclosed. The disclosed EGFR-TK inhibitors comprise a polyalkylene glycol moiety and / or a hydroxy-containing moiety and are characterized by improved solubility, biostability and bioavailability. Processes of preparing the disclosed EGFR-TK inhibitors and of radiolabeling same, via, for example, one-step radiosyntheses, are also disclosed.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD +1

Portable Microfluidic Radiosynthesis System for Positron Emission Tomography Biomarkers and Program Code

Methods and devices for a fully automated synthesis of radioactive compounds for imaging, such as by positron emission tomography (PET), in a fast, efficient and compact manner are disclosed. In particular, the various embodiments of the present invention provide an automated, stand-alone, hands-free operation of the entire radiosynthesis cycle on a microfluidic device with unrestricted gas flow through the reactor, starting with target water and yielding purified PET radiotracer within a period of time shorter than conventional chemistry systems. Accordingly, one aspect of the present invention is related to a microfluidic chip for radiosynthesis of a radiolabeled compound, comprising a reaction chamber, one or more flow channels connected to the reaction chamber, one or more vents connected to said reaction chamber, and one or more integrated valves to effect flow control in and out of said reaction chamber.
Owner:SIEMENS MEDICAL SOLUTIONS USA INC

Nucleophilic radiofluorination using microfabricated devices

A microscale solution for conducting [18F]fluoride phase transfer and subsequent radiosynthesis of 2-[18F]FDG that eliminates the azeotropic drying process. [18F]fluoride phase transfer is performed using an inexpensive disposable microchip. Additionally, each subsequent each step may be performed on the same single microchip.
Owner:STEEL COLIN +3

Microfluidic radiosynthesis system for positron emission tomography biomarkers

InactiveCN102083525AUltra efficient fractional distillation elutionEfficient fractional distillation elutionFixed microstructural devicesChemical/physical/physico-chemical microreactorsTime segmentEngineering
Methods and devices for a fully automated synthesis of radioactive compounds for imaging, such as by positron emission tomography (PET), in a fast, efficient and compact manner are disclosed. In particular, the various embodiments of the present invention provide an automated, stand-alone, hands-free operation of the entire radiosynthesis cycle on a microfluidic device with unrestricted gas flow through the reactor, starting with target water and yielding purified PET radiotracer within a period of time shorter than conventional chemistry systems. Accordingly, one aspect of the present invention is related to a microfluidic chip for radiosynthesis of a radiolabeled compound, comprising a reaction chamber, one or more flow channels connected to the reaction chamber, one or more vents connected to said reaction chamber, and one or more integrated valves to effect flow control in and out of said reaction chamber.
Owner:SIEMENS MEDICAL SOLUTIONS USA INC

2-fluoro-aniline quinazoline tumour positron imaging agents as well as preparation method and application thereof

The invention provides a 2-fluoro-aniline quinazoline compound labelled by F-18, wherein <18>F is produced by a circular accelerator via <18>O(pn)<18>F nuclear reaction and automatically synthesised by a radioactive synthesis module, and can also be produced by the existing domestic F-18 multifunctional synthesis device after process reformation. The 2-fluoro-aniline quinazoline compound provided by the invention is of an aniline quinazoline structure substituted by 2-bit positron nuclide fluorine-18, and can be modified on 6-bit, 7-bit and benzene ring connected with an amino group. The invention provides novel tumour positron imaging agents, wherein compared with <18>F-fluoro-deoxyglucose (<18>FDG), the imaging agents are specific, and capable of identifying the tumours highly expressed by an epidermal growth factor receptor (EGFR). The preparation method is reasonable in design, simple in labelling method, capable of realizing automatic production, and suitable for application. The structural general formula of the 2-fluoro-aniline quinazoline compound is defined in the specification.
Owner:ZHEJIANG UNIV

SYNTHESIS OF 2'-Deoxy-2'-[18F]FLUORO-5-METHYL-1-B-D-ARABINOFURANOSYLURACIL (18F-FMAU)

The present invention relates to methods of synthesizing 18F-FMAU. In particular, 18F-FMAU is synthesized using one-pot reaction conditions in the presence of Friedel-Crafts catalysts. The one-pot reaction conditions are incorporated into a fully automated cGMP-compliant radiosynthesis module, which results in a reduction in synthesis time and simplifies reaction conditions. The one-pot reaction conditions are also suitable for the production of 5-substitued thymidine or cytidine analogues. The products from the one-pot reaction (e.g. the labeled thymidine or cytidine analogues) can be used as probes for imaging tumor proliferative activity. More specifically, these [18F]-labeled thymidine or cytidine analogues can be used as a PET tracer for certain medical conditions, including, but not limited to, cancer disease, autoimmunity inflammation, and bone marrow transplant.
Owner:UNIV OF SOUTHERN CALIFORNIA

Polymer monoliths for solvent exchange in continuous flow microfluidic device

The present disclosure relates to the novel multistep procedure for preparation of polymer monoliths for use in solvent exchange, such as methods to exchange and activate fluoride ions on a flow through microfluidic chip for subsequent chemical synthesis. Methods according to the present disclosure include the application of such microfluidic platforms for rapid F18 radiosynthesis on a flow through microfluidic chip with high efficiency, followed by a subsequent nucleophilic fluorination reaction. Various other methods of exchanging and activating fluoride ions on a flow through microfluidic chip are also disclosed. Methods incorporating features of the present invention can be applicable to any flow through microfluidic device in any field, such as radiosyntheses, chemical syntheses, concentration of ions for environmental analyses and sample preparation such as concentrating minute amounts of analyte to improve the downstream detection.
Owner:RGT UNIV OF CALIFORNIA

2-<18>F-fluoropropionic acid isomers, synthesis method and application thereof

The invention relates to 2-<18>F-fluoropropionic acid isomers: R-2-<18>F-fluoropropionic acid (R-<18>F-FPA, formula 1) and S-2-<18>F-fluoropropionic acid (S-18F-FPA, formula 2), a synthesis method and application thereof in preparation of positron emission tomography (PET) imaging agent drugs. Enantiomer R- or S-2-trifluoromethanesulfonic acid-ethyl propionate is adopted as the precursor, and can be obtained by nucleophilic fluorination and hydrolysis two-step reaction. The chiral PET drug radiation synthesis method provided by the invention is simple, has high radiochemical yield, and is convenient for automatic synthesis, and the enantiomers can be used for differential diagnosis and therapeutic effect evaluation of tumors, cardiovascular and cerebrovascular diseases and neuropsychiatric disorders. (formula 1, and formula 2).
Owner:GUANGDONG HUIXUAN PHARMA TECH

Apparatus for the production of a radiopharmaceutical comprising a piercing device

ActiveCN107405595ABroad range radiochemical synthesisProcess control/regulationSugar derivativesChemical synthesisEngineering
The present invention provides a system for the production of a radiopharmaceutical including a radiosynthesis apparatus and a disposable cassette. The system of the invention includes a device that enables a position on the cassette to be freed for inclusion of an additional reagent vial. With the system of the invention a broader range of radiochemical syntheses can be envisaged using the cassette.
Owner:GE HEALTHCARE LTD

Modular system for radiosynthesis with multi-run capabilities and reduced risk of radiation exposure

Macro- and microfluidic devices and related technologies, and chemical processes using such devices. More specifically, the devices may be used for a fully automated synthesis of radioactive compounds for imaging, such as by positron emission tomography (PET), in an efficient, compact and safe to the operator manner. In particular, embodiments of the present invention relate to an automated, multi-run, microfluidic instrument for the multi-step synthesis of radiopharmaceuticals, such as PET probes, comprising a remote shielded mini-cell containing radiation-handing components.
Owner:SIEMENS MEDICAL SOLUTIONS USA INC

Positron-nuclide-labeled dansyl amido diphenylethylene compound and synthesis method and application thereof

The invention relates to an optics and positron emission tomography (PET) dual-mode developer (formula 1) targeted to apoptotic cells and beta-amyloid protein, namely, a positron-nuclide-labeled 4-dansyl amido-4'-diphenylethylene compound. A synthesis method of the compound includes the steps that dansyl targeted to apoptotic cells and 1,2-diphenylvinyl-amino targeted to beta-amyloid protein are bound together, and then labeling is conducted. The compound is simple in radiosynthesis method, high in radiochemical yield and convenient to synthesize automatically, has broad application prospects and can be applied to anti-tumor therapy monitoring and differential diagnosis and scientific research on neurological and psychotic disorders like Alzheimer disease (AD). The formula 1 is defined in the description.
Owner:GUANGDONG HUIXUAN PHARMA TECH

Direct synthesis of 18f-fluoromethoxy compounds for pet imaging and the provision of new precursors for direct radiosynthesis of protected derivatives of o-([18f]fluoromethyl) tyrosine

The invention describes novel direct synthesis methods for converting a precursor into a PET-tracer with a 18F-fluoromethoxy-group. The invention is also directed to novel and stable precursors for the direct radiosynthesis of protected derivatives of O- ([18F]Fluoromethyl) tyrosines.
Owner:PIRAMAL IMAGING SA

Radiofluorination

The present invention relates to 18F radio-chemistry and in particular to a method for synthesising radiofluorinated amides and amines. The method of the invention has particular application in the radiosynthesis of a variety of 18F-labelled positron emission tomography (PET) tracers.
Owner:HAMMERSMITH IMANET +1

Tumor PET imaging agent <68>Ga-NOTA-ADG and preparation method and application thereof

The invention relates to a tumor positron emission tomography(PET) imaging agent <68>Ga-NOTA-ADG and a preparation method and application thereof, and relates to synthesis of a labeling precursor of the PET imaging agent <68>Ga-NOTA-ADG and radiosynthesis of the <68>Ga-NOTA-ADG, wherein the precursor is used for labeling the <68>Ga-NOTA-ADG for the first time, and a result shows that the radiochemical yield of the preparation method is close to 100%. The positron imaging agent <68>Ga-NOTA-ADG provided by the invention can be used as a PET imaging probe for targeting tumors. Therefore, the <68>Ga-NOTA-ADG becomes a PET candidate imaging probe for the tumors. According to the invention, the radioactive chemical synthesis of the <68>Ga-NOTA-ADG is carried out for the first time, the preparation method is simple and rapid, and a foundation is laid for scientific research and clinical application of the <68>Ga-NOTA-ADG.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV

2-fluoro-aniline quinazoline tumour positron imaging agents as well as preparation method and application thereof

The invention provides a 2-fluoro-aniline quinazoline compound labelled by F-18, wherein 18 F is produced by a circular accelerator via 18O(pn)18F nuclear reaction and automatically synthesised by a radioactive synthesis module, and can also be produced by the existing domestic F-18 multifunctional synthesis device after process reformation. The 2-fluoro-aniline quinazoline compound provided by the invention is of an aniline quinazoline structure substituted by 2-bit positron nuclide fluorine-18, and can be modified on 6-bit, 7-bit and benzene ring connected with an amino group. The invention provides novel tumour positron imaging agents, wherein compared with 18F-fluoro-deoxyglucose (18FDG), the imaging agents are specific, and capable of identifying the tumours highly expressed by an epidermal growth factor receptor (EGFR). The preparation method is reasonable in design, simple in labelling method, capable of realizing automatic production, and suitable for application. The structural general formula of the 2-fluoro-aniline quinazoline compound is defined in the specification.
Owner:ZHEJIANG UNIV

Equipment for the production of radiopharmaceuticals including lancing devices

ActiveCN107405595BBroad range radiochemical synthesisProcess control/regulationSugar derivativesChemical synthesisRadiosynthesis
The present invention provides a system for producing a radiopharmaceutical comprising a radiosynthesis device and a disposable cassette. The system of the present invention includes means that allow the release of positions on the cartridge to include additional vials of reagents. With the system of the present invention, a wide range of radiochemical syntheses can be envisioned using the cassette.
Owner:GE HEALTHCARE LTD

Positron nuclide-labeled dansylamide stilbene compound, its synthesis method and application

The invention relates to an optics and positron emission tomography (PET) dual-mode developer (formula 1) targeted to apoptotic cells and beta-amyloid protein, namely, a positron-nuclide-labeled 4-dansyl amido-4'-diphenylethylene compound. A synthesis method of the compound includes the steps that dansyl targeted to apoptotic cells and 1,2-diphenylvinyl-amino targeted to beta-amyloid protein are bound together, and then labeling is conducted. The compound is simple in radiosynthesis method, high in radiochemical yield and convenient to synthesize automatically, has broad application prospects and can be applied to anti-tumor therapy monitoring and differential diagnosis and scientific research on neurological and psychotic disorders like Alzheimer disease (AD). The formula 1 is defined in the description.
Owner:GUANGDONG HUIXUAN PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products